Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

In the most recent trading session, Teladoc (TDOC) closed at $10.87, indicating a -1.9% shift from the previous trading day.

Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade

SAN DIEGO--(BUSINESS WIRE)---- $TDOC #TDOC--Robbins LLP is Investigating Allegations that Teladoc Health, Co. (TDOC) Misled Investors Regarding its Marketing Spend and its Impact on Revenue.

Robbins LLP Urges TDOC Stockholders With Large Losses to Contact the Firm About Their Rights in the Teladoc Health, Inc. Class Action

PayPal

Zoom Video

Home run hitters tend to also have a lot of strikeouts. Swinging for the fences means you're going to miss a lot of balls, too.

The 3 Most Undervalued Cathie Wood Stocks to Buy in June 2024

NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Teladoc Health Inc. ("Teladoc" or the "Company") (NYSE:TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Teladoc Health Inc. - TDOC

Cathie Wood has reduced her position in Teladoc Health, a stock found in her flagship and healthcare funds. The telemedicine leader has struggled in recent years and now is on the hunt for a new leader.

Cathie Wood Has Been Steadily Selling Shares of This Growth Stock. Should You?

In the closing of the recent trading day, Teladoc (TDOC) stood at $11.15, denoting a -1.85% change from the preceding trading day.

Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note

NEW YORK , May 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC). Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Class Action Filed Against Teladoc Health, Inc. (TDOC) Seeking Recovery for Investors - Contact The Gross Law Firm

Bionano Genomics

CVS Health

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth.

3 Sorry Healthcare Stocks to Sell in May While You Still Can

NEW YORK , May 28, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the "Class Period"), of the important July 16, 2024 lead plaintiff deadline. SO WHAT: If you purchased Teladoc stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TDOC

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Teladoc business and prospects, resulting in its stock trading at inflated prices.

TDOC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Teladoc Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)---- $TDOC #TeladocHealthInc--Robbins LLP is Investigating Allegations that Teladoc Health, Co. (TDOC) Misled Investors Regarding its Marketing Spend and its Impact on Revenue.

Teladoc Health, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the TDOC Class Action

NEW YORK , May 21, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

TDOC INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TDOC

Unity Software

Under Armour

Three stocks might be considered potential opportunities to purchase stocks at a discount. These companies are involved in various industries, which makes solid ideas for possible recoveries and substantial profits.

Buy the Dip: 3 Stocks Ready to Rebound for Big Returns

NEW YORK , May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC). Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Shareholders of Teladoc Health, Inc.(TDOC) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 16, 2024. SO WHAT: If you purchased Teladoc stock during the Class Period you.

TDOC INVESTOR NEWS: ROSEN, LEADING INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

NEW YORK--(BUSINESS WIRE)---- $TDOC #Investigation--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities during the period of November 2, 2022 through February 20, 2024, inclusive (“the Class Period”). Investors have until July 16, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click h.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Teladoc Health, Inc. (TDOC) Investors

TDOC INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Teladoc Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / May 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Levi & Korsinsky Reminds Shareholders of an Investigation into Teladoc Health, Inc. (TDOC) Regarding Potential Securities Fraud Allegations

BARK

NIKE

Finding stocks to sell in 2024 is straightforward, but actually executing those trades is another matter. As always, bearish sentiment surrounds the Magnificent Seven as the S&P 500 hits all-time highs despite sweeping tech layoffs and overall economic unease.

From Hype to Bust: The Downfall of Teladoc, Bark and Nike Stocks

Pfizer

While healthcare is broadly resilient in times of economic stress, each company needs its own evaluation. Pfizer is dealing with a period of transition, but its business has only been bolstered by pandemic successes.

2 Top Growth Stocks Down 24% and 50% to Buy With $100

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Investors who lost money on Teladoc Health, Inc. should contact Levi & Korsinsky about an ongoing investigation - TDOC

NEW YORK, NY / ACCESSWIRE / May 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Teladoc Health, Inc. (TDOC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

AdaptHealth Corp

Celestica

Finding investing opportunities in the market might be challenging. Nevertheless, three equities stick out due to their ability to yield large profits during volatility.

3 High-Potential Stocks to Buy at Rock-Bottom Prices

NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

Levi & Korsinsky Announces an Investigation on Behalf of Teladoc Health, Inc. (TDOC) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / May 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teladoc Health, Inc. ("Teladoc") (NYSE:TDOC) concerning possible violations of federal securities laws. On February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023.

News for Teladoc Stock (TDOC)